Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KRT-232 + TL-895 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KRT-232 | KRT 232|KRT232|AMG232|AMG 232|AMG-232|Navtemadlin | MDM2 Inhibitor 23 | KRT-232 (AMG 232) is a potent inhibitor of the MDM2-p53 interaction, and inhibits proliferation of tumor cells in a p53 dependent manner (PMID: 24456472, PMID: 32234759). | |
TL-895 | TL895|TL 895 | TL-895 is a tyrosine kinase inhibitor that binds to tyrosine kinases in tumor cells, potentially leading to inhibition of tumor cell proliferation, tumor angiogenesis, and inflammatory immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04669067 | Phase Ib/II | KRT-232 + TL-895 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |